Arecor Therapeutics plc (AIM:AREC)
London
· Delayed Price · Currency is GBP · Price in GBX 70.00
+4.00 (6.06%)
Apr 28, 2026, 2:15 PM GMT
Arecor Therapeutics Income Statement
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Revenue | 1.71 | 5.05 | 4.57 | 2.4 | 1.16 | Upgrade
|
| Revenue Growth (YoY) | -66.08% | 10.50% | 90.30% | 107.51% | -31.80% | Upgrade
|
| Cost of Revenue | 0.45 | 3.51 | 3.32 | - | - | Upgrade
|
| Gross Profit | 1.27 | 1.54 | 1.25 | 2.4 | 1.16 | Upgrade
|
| Selling, General & Admin | 3.17 | 6.18 | 6.17 | 5.38 | 2.39 | Upgrade
|
| Research & Development | 2.69 | 3.04 | 5.4 | 8.61 | 5.39 | Upgrade
|
| Other Operating Expenses | -0.56 | -0.27 | -1.14 | -1.25 | -0.64 | Upgrade
|
| Operating Expenses | 5.31 | 8.95 | 10.43 | 12.74 | 7.14 | Upgrade
|
| Operating Income | -4.05 | -7.41 | -9.18 | -10.34 | -5.98 | Upgrade
|
| Interest Expense | -0.01 | -0.02 | -0.02 | -0.02 | -0.02 | Upgrade
|
| Interest & Investment Income | 0.07 | 0.1 | 0.28 | 0.11 | 0 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | 0.01 | - | - | Upgrade
|
| EBT Excluding Unusual Items | -3.98 | -7.33 | -8.9 | -10.25 | -6 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | -0.17 | - | Upgrade
|
| Impairment of Goodwill | - | -1.48 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 4.98 | - | - | - | - | Upgrade
|
| Asset Writedown | - | -1.8 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | -0.95 | Upgrade
|
| Pretax Income | 0.99 | -10.62 | -8.9 | -10.42 | -6.95 | Upgrade
|
| Income Tax Expense | 0.06 | -0.38 | -0.35 | -1.16 | -0.78 | Upgrade
|
| Earnings From Continuing Operations | 0.93 | -10.24 | -8.55 | -9.26 | -6.17 | Upgrade
|
| Earnings From Discontinued Operations | -0.27 | - | - | - | - | Upgrade
|
| Net Income | 0.66 | -10.24 | -8.55 | -9.26 | -6.17 | Upgrade
|
| Net Income to Common | 0.66 | -10.24 | -8.55 | -9.26 | -6.17 | Upgrade
|
| Shares Outstanding (Basic) | 38 | 33 | 31 | 29 | 23 | Upgrade
|
| Shares Outstanding (Diluted) | 39 | 33 | 31 | 29 | 23 | Upgrade
|
| Shares Change (YoY) | 17.94% | 9.20% | 5.83% | 25.63% | 41.77% | Upgrade
|
| EPS (Basic) | 0.02 | -0.31 | -0.28 | -0.32 | -0.27 | Upgrade
|
| EPS (Diluted) | 0.02 | -0.31 | -0.28 | -0.32 | -0.27 | Upgrade
|
| Free Cash Flow | -2.46 | -9.18 | -5.99 | -11.08 | -5.52 | Upgrade
|
| Free Cash Flow Per Share | -0.06 | -0.27 | -0.20 | -0.38 | -0.24 | Upgrade
|
| Gross Margin | 73.86% | 30.54% | 27.36% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -236.00% | -146.63% | -200.63% | -430.34% | -516.15% | Upgrade
|
| Profit Margin | 38.74% | -202.57% | -187.05% | -385.35% | -532.73% | Upgrade
|
| Free Cash Flow Margin | -143.64% | -181.63% | -131.03% | -461.05% | -476.60% | Upgrade
|
| EBITDA | -3.84 | -7.1 | -8.88 | -10.14 | -5.9 | Upgrade
|
| EBITDA Margin | -224.04% | -140.47% | -194.18% | - | - | Upgrade
|
| D&A For EBITDA | 0.21 | 0.31 | 0.3 | 0.2 | 0.08 | Upgrade
|
| EBIT | -4.05 | -7.41 | -9.18 | -10.34 | -5.98 | Upgrade
|
| EBIT Margin | -236.00% | -146.63% | -200.63% | - | - | Upgrade
|
| Effective Tax Rate | 6.24% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.